From the Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
J Natl Compr Canc Netw. 2016 Oct;14(10):1313-1320. doi: 10.6004/jnccn.2016.0138.
In recent years, various new agents have been investigated for the treatment of advanced gastric cancer (AGC). The anti-HER2 antibody trastuzumab has been shown to prolong the overall survival of patients with HER2-positive AGC and has become a standard treatment. However, lapatinib, or ado-trastuzumab emtansine (T-DM1), did not show survival benefit in AGC, although it has shown remarkable efficacy for HER2-positive breast cancer. The efficacy of the anti-vascular endothelial growth factor receptor monoclonal antibody ramucirumab for pretreated gastric cancer is a milestone for antiangiogenic therapy for AGC. Early clinical trials of TAS-118, TAS-102, and STAT3 inhibitors; IMAB362 (anti-Claudin 18.2); and immune checkpoint inhibitors are all encouraging. These findings warrant further evaluation in larger clinical trials.
近年来，已经有多种新的药物被研究用于治疗晚期胃癌（AGC）。抗 HER2 抗体曲妥珠单抗已被证明能延长 HER2 阳性 AGC 患者的总生存期，已成为一种标准治疗方法。然而，拉帕替尼或 ado-trastuzumab emtansine（T-DM1）在 AGC 中并未显示生存获益，尽管它对 HER2 阳性乳腺癌有显著疗效。抗血管内皮生长因子受体单克隆抗体雷莫芦单抗用于预处理胃癌的疗效是 AGC 抗血管生成治疗的一个里程碑。TAS-118、TAS-102 和 STAT3 抑制剂、IMAB362（抗 Claudin 18.2）和免疫检查点抑制剂的早期临床试验结果均令人鼓舞。这些发现需要在更大的临床试验中进一步评估。
